trimetrexate has been researched along with Skin Neoplasms in 1 studies
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.
Skin Neoplasms: Tumors or cancer of the SKIN.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harris, PJ | 1 |
1 other study available for trimetrexate and Skin Neoplasms
| Article | Year |
|---|---|
Trimetrexate glucuronate associated with anti-Kaposi sarcoma effect.
Topics: Adult; AIDS-Related Opportunistic Infections; Antineoplastic Agents; Drug Combinations; Glucuronates | 1996 |